2023 World Conference on Lung Cancer (Posters)-P2.19. [DREAM] Double Lung Transplant Registry Aimed for Lung-Limited Malignancies - A Prospective Registry Study for Medically Refractory Cancers

P2.19. [DREAM] Double Lung Transplant Registry Aimed for Lung-Limited Malignancies - A Prospective Registry Study for Medically Refractory Cancers - PDF(Abstract)

Back to course

Pdf Summary

The presentation titled "[DREAM] Double Lung Transplant Registry Aimed for Lung-Limited Malignancies - A Prospective Registry Study for Medically Refractory Cancers" discusses the use of double lung transplantation as a treatment option for lung-limited malignancies. The study is focused on patients who have primary lung cancers or metastatic cancers in the lungs. The researchers aim to evaluate the outcomes of patients who undergo double lung transplantation and to investigate the correlation between molecular and genetic biomarkers and prognosis.<br /><br />The study is a prospective registration trial with a duration of 10 years, including surveillance. Recruitment is planned to take place during the first 5 years of the study, with a goal of enrolling 75 participants through the Northwestern Medicine Clinical Programs. The essential criteria for eligibility include the absence of extrapulmonary metastasis, failure or infeasibility of standard or experimental oncological treatments, and meeting the general criteria for lung transplant evaluation and listing.<br /><br />The study is divided into two cohorts. Cohort A focuses on patients with primary lung cancers, including invasive mucinous/non-mucinous non-small cell lung cancers and multifocal carcinomas. Cohort B includes patients with metastatic cancers to the lungs, such as germ cell tumors, head & neck tumors, colorectal tumors, renal cell tumors, and testicular cancers.<br /><br />The presentation mentions that adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) are considered "special circumstances" for lung transplantation, according to a consensus document from the International Society for Heart and Lung Transplantation (ISHLT). Previous studies have reported a 5-year survival rate of over 50% for bilateral sequential lung transplantation in patients with multifocal lung adenocarcinoma, invasive adenocarcinoma, and non-small cell lung cancer.<br /><br />The presentation also notes that there is an unmet need for patients with lung-limited metastasis after successful treatment for primary tumors such as sarcomas or colorectal cancer. The researchers suggest that lung transplantation could be explored as a treatment option for these patients, similar to liver transplantation for patients with liver-confined metastases from colorectal cancer.<br /><br />The clinical trial registry number for this study is NCT05671887, and enrollment began on November 16, 2022. As of April 12, 2023, three participants have been recruited.

Asset Subtitle

Young Kwang Chae

Meta Tag

Speaker Young Kwang Chae

Topic Mesothelioma, Thymoma & Other Thoracic Tumors: Clinical Trial in Progress

Keywords

Double Lung Transplant Registry

Lung-Limited Malignancies

Prospective Registry Study

Medically Refractory Cancers

Primary Lung Cancers

Metastatic Cancers in the Lungs

Molecular and Genetic Biomarkers

Prognosis

Extrapulmonary Metastasis

Lung Transplant Evaluation